A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Conditions
- Carcinoma, Renal CellAdvanced Renal Cell CarcinomaRenal CancerRenal NeoplasmClear Cell Renal Cell CarcinomaMetastatic Renal Cell CarcinomaClear-cell Metastatic Renal Cell CarcinomaCarcinoma, Renal Cell MetastasisAdvanced or Metastatic Renal Cell CarcinomaCarcinoma, Renal Cell, Advanced
- Interventions
- Biological: PF-08634404Drug: Combination 1Drug: Combination 2
- Registration Number
- NCT07227415
- Lead Sponsor
- Pfizer
- Brief Summary
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them.
To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer.
Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 224
- 18 years of age or older at screening
- Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC with diagnosis confirmed by histology/cytology
- At least one measurable (as defined by the investigator) and untreated lesion
- Adequate hematologic, hepatic, cardiac and renal function
- No prior systemic therapy for RCC (immunotherapy after surgery is allowed if received >12 months prior)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- All International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) based risk categories.
Participants may be excluded if they meet any of the following:
- Known active brain lesions including leptomeningeal metastasis, brainstem, meningeal or spinal cord metastases or compression.
- Clinically significant risk of haemorrhage or fistula
- History of another malignancy within 3 years
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- active autoimmune diseases requiring systemic treatment within the past 2 years
- uncontrolled cardiac and other comorbidities within 6 months prior to the first dose
- Major surgery or severe trauma within 4 weeks before the first dose, or planned major surgery during the study
- History of severe bleeding tendency or coagulation dysfunction
- History of oesophageal varices, severe ulcers, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess
- Acute, chronic or symptomatic infections
- Participants with history of immunodeficiency
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Cohort A PF-08634404 Participants will receive PF-08634404 IV. Cohort B PF-08634404 Participants will receive PF-08634404 in combination with drug 1. Cohort B Combination 1 Participants will receive PF-08634404 in combination with drug 1. Cohort C PF-08634404 Participants will receive PF-08634404 IV in combination with drug 2. Cohort C Combination 2 Participants will receive PF-08634404 IV in combination with drug 2.
- Primary Outcome Measures
Name Time Method Confirmed objective response rate (ORR) using RECIST v1.1 as assessed by investigator Up to approximately 3 years ORR is defined as the proportion of participants in the analysis population having a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST v1.1 as assessed by investigator.
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Through 90 days after the last study intervention (Up to approximately 3 years) AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.
Number of participants with dose limiting toxicity (DLT) Though end of DLT evaluation period (Up to approximately 3 years) The number of participants who experienced DLTs during the DLT evaluation period in Cohort B (combination 1) and Cohort C (combination 2).
- Secondary Outcome Measures
Name Time Method Duration of Response (DOR) per RECIST v1.1 by investigator Up to approximately 3 years DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first.
Progression Free Survival (PFS) per RECIST v1.1 by investigator Up to approximately 3 years Progression-free survival is defined as the time from the date of randomization to the date of the first documentation of objective progressive disease (PD) assessed by investigator per RECIST v1.1, or death due to any cause, whichever occurs first.
Overall Survival (OS) Up to approximately 3 years Overall survival defined as the time from the date of randomization to the date of death due to any cause.
Number of Participants With Clinical Laboratory Abnormalities Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (approximately 3 years) laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0) and timing
Pharmacokinetics (PK): Serum concentration of PF-08634404 Up to 37 days after the last dose of treatment Pre-dose and post dose concentrations of PF-08634404
Incidence of Anti-Drug Antibody (ADA) against PF-08634404 Up to 37 days after the last dose of treatment To evaluate the immunogenicity of PF-08634404